From the College of Pharmacy (K.K.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology & Biostatistics (K.K., A.H., S.H., Y.L.), Karolinska Institutet, Stockholm, Sweden; Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; Department of Neurology (A.S.), UT Southwestern, Dallas, TX; Department of Internal Medicine (C.D., C.N.B., R.A.M.), Department of Psychiatry (J.B.), and Department of Community Health Sciences (J.B., R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Department of Biostatistics (G.R.C., A.P., H.K.T.), University of Alabama at Birmingham; Department of Clinical Health Psychology (L.A.G.), and Department of Rheumatology (C.A.H.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Icahn School of Medicine at Mount Sinai (F.L.), New York, NY; Department of Clinical Neuroscience (K.A.M.), Karolinska Institutet, Stockholm, Sweden; Department of Community Health Sciences (S.B.P.), Cumming School of Medicine, University of Calgary, Alberta, Canada; and Department of Neurology (J.S.W.), McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston.
Neurology. 2023 Aug 1;101(5):e522-e532. doi: 10.1212/WNL.0000000000207457. Epub 2023 Jun 8.
Depression is common in multiple sclerosis (MS) and is associated with faster disability progression. The etiology of comorbid depression in MS remains poorly understood. Identification of individuals with a high risk of depression, through polygenic scores (PGS), may facilitate earlier identification. Previous genetic studies of depression considered depression as a primary disorder, not a comorbidity, and thus, findings may not generalize to MS. Body mass index (BMI) is a risk factor of both MS and depression, and its association may highlight differences in depression in MS. To improve the understanding of comorbid depression in MS, we will investigate PGS in people with MS, with the hypothesis that a higher depression PGS is associated with increased odds for comorbid depression in MS.
Samples from 3 sources (Canada, UK Biobank, and the United States) were used. Individuals were grouped into cases (MS/comorbid depression) and compared with 3 control groups: MS/no depression, depression/no immune disease, and healthy persons. We used 3 depression definitions: lifetime clinical diagnoses, self-reported diagnoses, and depressive symptoms. The PGS were tested in association with depression using regression.
A total of 106,682 individuals of European genetic ancestry were used: Canada (n = 370; 213 with MS), UK Biobank (n = 105,734; 1,390 with MS), and the United States (n = 578 with MS). Meta-analyses revealed individuals with MS and depression had a higher depression PGS compared with both individuals with MS without depression (odds ratio range per SD 1.29-1.38, < 0.05) and healthy controls (odds ratio range per SD 1.49-1.53, < 0.025), regardless of the definition applied and when sex stratified. The BMI PGS was associated with depressive symptoms ( ≤ 0.001). The depression PGS did not differ between depression occurring as a comorbid condition with MS or as the primary condition (odds ratio range per SD 1.03-1.13, all > 0.05).
A higher depression genetic burden was associated with approximately 30%-40% increased odds of depression in European genetic ancestry participants with MS compared with those without depression and was no different compared with those with depression and no comorbid immune disease. This study paves the way for further investigations into the possible use of PGS for assessing psychiatric disorder risk in MS and its application to non-European genetic ancestries.
抑郁症在多发性硬化症(MS)中很常见,并且与残疾进展更快有关。MS 合并抑郁的病因仍知之甚少。通过多基因评分(PGS)来识别具有高抑郁风险的个体,可以更早地识别。以前关于抑郁症的遗传研究将抑郁症视为原发性疾病,而不是合并症,因此研究结果可能无法推广到 MS。体重指数(BMI)是 MS 和抑郁症的危险因素,其相关性可能突出了 MS 中抑郁症的差异。为了更好地了解 MS 中的合并性抑郁,我们将研究 MS 患者的 PGS,假设较高的抑郁 PGS 与 MS 合并性抑郁的几率增加有关。
使用了来自 3 个来源(加拿大、英国生物库和美国)的样本。将个体分为病例(MS/合并性抑郁),并与 3 个对照组进行比较:MS/无抑郁、抑郁/无免疫性疾病和健康个体。我们使用了 3 种抑郁定义:终生临床诊断、自我报告诊断和抑郁症状。使用回归分析测试了 PGS 与抑郁的关联。
共使用了 106682 名欧洲遗传血统的个体:加拿大(n=370;213 名 MS)、英国生物库(n=105734;1390 名 MS)和美国(n=578 名 MS)。荟萃分析显示,与没有 MS 抑郁的个体(每个 SD 的比值比范围为 1.29-1.38, < 0.05)和健康对照者(每个 SD 的比值比范围为 1.49-1.53, < 0.025)相比,患有 MS 和抑郁症的个体具有更高的抑郁 PGS。无论应用何种定义和性别分层,结果均如此。BMI PGS 与抑郁症状相关(≤0.001)。MS 合并抑郁或作为原发性疾病的抑郁 PGS 无差异(每个 SD 的比值比范围为 1.03-1.13,均>0.05)。
与没有抑郁的 MS 参与者相比,欧洲遗传血统的 MS 参与者的抑郁遗传负担更高,与抑郁相关的几率增加了约 30%-40%,与患有抑郁但无合并免疫性疾病的参与者相比,差异无统计学意义。这项研究为进一步研究 PGS 在评估 MS 中精神疾病风险及其在非欧洲遗传血统中的应用铺平了道路。